



KINEXUS

Kinexus Announces Six New Phospho-Site Profiling Services

Kinetworks™ Phosphoprotein Services designed for drug discovery

FOR IMMEDIATE RELEASE JULY 22, 2005

VANCOUVER, British Columbia – Kinexus Bioinformatics Corporation, a Canadian proteomics company, is pleased to announce the release of six new Kinetworks™ Phosphoprotein Screening Services, KPSS 7.0 through 12.0, for simultaneously tracking the phosphorylation status of over 200 different regulatory sites in cell signaling proteins. These 6 new screens are based on themes of cell proliferation (KPSS 7.0), stress (KPSS 8.0) neurobiology (KPSS 9.0), cell cycle status (KPSS 10.0), protein kinases (KPSS 11.0) and substrates of kinases (KPSS 12.0). The KPSS 7.0, 8.0 and 9.0 screens were developed in collaboration with Biosource International, a life sciences company that develops and markets biologically active reagents for pharmaceutical and biomedical research. The unique capabilities of the Kinetworks™ profiling services were also recently featured in an article entitled “Kinase Screening Services Probe Signalling Pathways” profiled in The Scientist Magazine (www.the-scientist.com).

The Kinetworks™ approach for the detection of phosphoproteins is designed to assist biomedical researchers in the discovery of new drug targets, new drugs and the molecular diagnosis of disease. The phosphoprotein screens have already uncovered promising research leads in important disease states, including ALS, Alzheimer’s, and Parkinson’s disease. “Our proteomic services provide insights into new potential drug targets while at the same time advancing the signal transduction field in a quantum way over other approaches,” said Dr. Steven Pelech, President and Founder of Kinexus and a Professor at the University of British Columbia. There are over 40 publications referencing the Kinetworks™ technology available online at www.kinexus.ca. Kinexus currently offers 15 different profiling services for quantification of over 500 proteins for expression and phosphorylation. In September 2005, Kinexus is launching KiNET, a bioinformatics service that will provide clients with access to a proprietary on-line, functional proteomics database with quantitative information on hundreds of different proteins in hundreds of different model systems.

Kinexus Bioinformatics Corporation is a private, biopharmaceutical company engaged in the research and development of innovative methods to understand the relationships of signaling proteins in cellular communication networks. The application of this knowledge positions Kinexus and its clients in drug development, rational drug design, disease diagnosis and personalized therapies to improve human health.

**For further information, please contact Kinexus Bioinformatics Corporation
toll free at 1-866-KINEXUS or visit our website at www.kinexus.ca**

PRESS RELEASE - 2005 JULY 22